Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin

Progress in Neurobiology

Volumn 99, Issue 2, 2012, Pages 128-148

  Chong, Zhao Zhong ^a,c   Shang, Yan Chen ^a,c   Wang, Shaohui ^a,c   Maiese, Kenneth ^a,b,c  

^a Laboratory of Cellular and Molecular Signaling   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c New Jersey Health Sciences University   (United States)

Author keywords

Apoptosis; Autophagy; MTOR; Neurodegeneration; Rapamycin; Stem cells

Indexed keywords

HAMARTIN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RIBOSOME PROTEIN; SCAFFOLD PROTEIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TAU PROTEIN; TUBERIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN ISCHEMIA; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; ENDOTHELIUM CELL; EPILEPSY; EPILEPTIC DISCHARGE; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; INFLAMMATORY CELL; INJURY; LHERMITTE DUCLOS DISEASE; NERVOUS SYSTEM TUMOR; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; STEM CELL;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; TOR SERINE-THREONINE KINASES;

EID: 84867897183     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.08.001     Document Type: Review

References (381)

1. Abel T.W., Baker S.J., Fraser M.M., Tihan T., Nelson J.S., Yachnis A.T., Bouffard J.P., Mena H., Burger P.C., Eberhart C.G. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. Journal of Neuropathology & Experimental Neurology 2005, 64:341-349.
2. Abraham R.T. mTOR as a positive regulator of tumor cell responses to hypoxia. Current Topics in Microbiology and Immunology 2004, 279:299-319.
3. Acosta-Jaquez H.A., Keller J.A., Foster K.G., Ekim B., Soliman G.A., Feener E.P., Ballif B.A., Fingar D.C. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Molecular and Cellular Biology 2009, 29:4308-4324.
4. Aimbetov R., Chen C.H., Bulgakova O., Abetov D., Bissenbaev A.K., Bersimbaev R.I., Sarbassov D.D. Integrity of mTORC2 is dependent on the rictor Gly-934 site. Oncogene 2011.
5. Akcakanat A., Singh G., Hung M.C., Meric-Bernstam F. Rapamycin regulates the phosphorylation of rictor. Biochemical and Biophysical Research Communication 2007, 362:330-333.
6. Aksu U., Demirci C., Ince C. The pathogenesis of acute kidney injury and the toxic triangle of oxygen, reactive oxygen species and nitric oxide. Contributions to Nephrology 2011, 174:119-128.
7. Ammar H.I., Saba S., Ammar R.I., Elsayed L.A., Ghaly W.B., Dhingra S. Erythropoietin protects against doxorubicin-induced heart failure. American Journal of Physiology Heart and Circulatory Physiology 2011, 301:H2413-H2421.
8. An W.L., Cowburn R.F., Li L., Braak H., Alafuzoff I., Iqbal K., Iqbal I.G., Winblad B., Pei J.J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. American Journal of Pathology 2003, 163:591-607.
9. Andreucci M., Fuiano G., Presta P., Lucisano G., Leone F., Fuiano L., Bisesti V., Esposito P., Russo D., Memoli B., Faga T., Michael A. Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Proliferation 2009, 42:554-561.
10. Asaithambi A., Kanthasamy A., Saminathan H., Anantharam V., Kanthasamy A.G. Protein kinase D1 (PKD1) activation mediates a compensatory protective response during early stages of oxidative stress-induced neuronal degeneration. Molecular Neurodegeneration 2011, 6:43.
11. Astrinidis A., Senapedis W., Coleman T.R., Henske E.P. Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. Journal of Biological Chemistry 2003, 278:51372-51379.
12. Baba H., Sakurai M., Abe K., Tominaga R. Autophagy-mediated stress response in motor neuron after transient ischemia in rabbits. Journal of Vascular Surgery 2009, 50:381-387.
13. Bach J.P., Mengel D., Wahle T., Kautz A., Balzer-Geldsetzer M., Al-Abed Y., Dodel R., Bacher M. The role of CNI-1493 in the function of primary microglia with respect to amyloid-beta. Journal of Alzheimers Disease 2011, 26:69-80.
14. Bai X., Ma D., Liu A., Shen X., Wang Q.J., Liu Y., Jiang Y. Rheb activates mTOR by antagonizing its endogenous inhibitor FKBP38. Science 2007, 318:977-980.
15. Bailey T.J., Fossum S.L., Fimbel S.M., Montgomery J.E., Hyde D.R. The inhibitor of phagocytosis O-phospho-L-serine, suppresses Muller glia proliferation and cone cell regeneration in the light-damaged zebrafish retina. Experimental Eye Research 2010, 91:601-612.
16. Bains M., Zaegel V., Mize-Berge J., Heidenreich K.A. IGF-I stimulates Rab7-RILP interaction during neuronal autophagy. Neuroscience Letters 2010.
17. Bajda M., Guzior N., Ignasik M., Malawska B. Multi-target-directed ligands in Alzheimer's disease treatment. Current Medicinal Chemistry 2011, 18:4949-4975.
18. Balan V., Miller G.S., Kaplun L., Balan K., Chong Z.Z., Li F., Kaplun A., VanBerkum M.F., Arking R., Freeman D.C., Maiese K., Tzivion G. Life span extension and neuronal cell protection by Drosophila nicotinamidase. Journal of Biological Chemistry 2008, 283:27810-27819.
19. Banach M., Piskorska B., Czuczwar S., Borowicz K. Nitric oxide, epileptic seizures, and action of antiepileptic drugs. CNS & Neurological Disorders Drug Targets 2011.
20. Basile L.A., Ellefson D., Gluzman-Poltorak Z., Junes-Gill K., Mar V., Mendonca S., Miller J.D., Tom J., Trinh A., Gallaher T.K. HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS ONE 2012, 7:e30434.
21. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Reviews Drug Discovery 2011, 10:868-880.
22. Bhandari B.K., Feliers D., Duraisamy S., Stewart J.L., Gingras A.C., Abboud H.E., Choudhury G.G., Sonenberg N., Kasinath B.S. Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney International 2001, 59:866-875.
23. Bhaskar K., Miller M., Chludzinski A., Herrup K., Zagorski M., Lamb B.T. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Molecular Neurodegeneration 2009, 4:14.
24. Blommaart E.F., Luiken J.J., Blommaart P.J., van Woerkom G.M., Meijer A.J. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. Journal of Biological Chemistry 1995, 270:2320-2326.
25. Blundell J., Kouser M., Powell C.M. Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Neurobiology of Learning and Memory 2008, 90:28-35.
26. Boulbes D., Chen C.H., Shaikenov T., Agarwal N.K., Peterson T.R., Addona T.A., Keshishian H., Carr S.A., Magnuson M.A., Sabatini D.M., Sarbassov dos D. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Molecular Cancer Research 2010, 8:896-906.
27. Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., Witters L.A., Ellisen L.W., Kaelin W.G. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Development 2004, 18:2893-2904.
28. Brunner S., Huber B.C., Weinberger T., Vallaster M., Wollenweber T., Gerbitz A., Hacker M., Franz W.M. Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction. Journal of Cellular and Molecular Medicine 2012, 16:152-159.
29. Bryce A.H., Rao R., Sarkaria J., Reid J.M., Qi Y., Qin R., James C.D., Jenkins R.B., Boni J., Erlichman C., Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Investigational New Drugs 2011.
30. Buckmaster P.S., Ingram E.A., Wen X. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. Journal of Neuroscience 2009, 29:8259-8269.
31. Budanov A.V., Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134:451-460.
32. Cai S.L., Tee A.R., Short J.D., Bergeron J.M., Kim J., Shen J., Guo R., Johnson C.L., Kiguchi K., Walker C.L. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. Journal of Cell Biology 2006, 173:279-289.
33. Campos-Esparza M.R., Sanchez-Gomez M.V., Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium 2009, 45:358-368.
34. Canu N., Tufi R., Serafino A.L., Amadoro G., Ciotti M.T., Calissano P. Role of the autophagic-lysosomal system on low potassium-induced apoptosis in cultured cerebellar granule cells. Journal of Neurochemistry 2005, 92:1228-1242.
35. Caprara C., Grimm C. From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Progress in Retinal and Eye Research 2012, 31:89-119.
36. Carayol N., Vakana E., Sassano A., Kaur S., Goussetis D.J., Glaser H., Druker B.J., Donato N.J., Altman J.K., Barr S., Platanias L.C. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proceedings of the National Academy of Sciences United States of America 2010, 107:12469-12474.
37. Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P., Roux P.P. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Current Biology 2008, 18:1269-1277.
38. Chalhoub S., Langston C.E., Farrelly J. The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases. Journal of Veterinary Internal Medicine 2012, 26:363-369.
39. Chalkias A., Xanthos T. Post-cardiac arrest brain injury: pathophysiology and treatment. Journal of Neurological Sciences 2012, 315:1-8.
40. Chano T., Okabe H., Hulette C.M. RB1CC1 insufficiency causes neuronal atrophy through mTOR signaling alteration and involved in the pathology of Alzheimer's diseases. Brain Research 2007, 1168:97-105.
41. Chen C., Liu Y., Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Science Signaling 2009, 2:ra75.
42. Chen C.H., Sarbassov dos D. The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. Journal of Biological Chemistry 2011, 286:40386-40394.
43. Chen E.J., Kaiser C.A. LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway. Journal of Cell Biology 2003, 161:333-347.
44. Chen J., Zheng X.F., Brown E.J., Schreiber S.L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proceedings of the National Academy of Sciences United States of America 1995, 92:4947-4951.
45. Chen J.X., Tuo Q., Liao D.F., Zeng H. Inhibition of protein tyrosine phosphatase improves angiogenesis via enhancing Ang-1/Tie-2 signaling in diabetes. Experimental Diabetes Research 2012, 2012:836759.
46. Chen L., Xu B., Liu L., Luo Y., Yin J., Zhou H., Chen W., Shen T., Han X., Huang S. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Laboratory Investigation 2010, 90:762-773.
47. Chen T.J., Wang D.C., Chen S.S. Amyloid-beta interrupts the PI3K-Akt-mTOR signaling pathway that could be involved in brain-derived neurotrophic factor-induced Arc expression in rat cortical neurons. Journal of Neuroscience Research 2009, 87:2297-2307.
48. Chiang G.G., Abraham R.T. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. Journal of Biological Chemistry 2005, 280:25485-25490.
49. Choi K.C., Kim S.H., Ha J.Y., Kim S.T., Son J.H. A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death. Journal of Neurochemistry 2010, 112:366-376.
50. Chong Z.Z., Hou J., Shang Y.C., Wang S., Maiese K. EPO Relies upon novel signaling of wnt1 that requires Akt1, FoxO3a, GSK-3beta, and beta-catenin to foster vascular integrity during experimental diabetes. Current Neurovascular Research 2011, 8:103-120.
51. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002, 106:2973-2979.
52. Chong Z.Z., Kang J.Q., Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. British Journal of Pharmacology 2003, 138:1107-1118.
53. Chong Z.Z., Kang J.Q., Maiese K. AKT1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3, and 9. Experimental Cell Research 2004, 296:196-207.
54. Chong Z.Z., Li F., Maiese K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histology and Histopathology 2005, 20:299-315.
55. Chong Z.Z., Li F., Maiese K. Employing new cellular therapeutic targets for Alzheimer's disease: a change for the better?. Current Neurovascular Research 2005, 2:55-72.
56. Chong Z.Z., Li F., Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Current Neurovascular Research. 2005, 2:387-399.
57. Chong Z.Z., Li F., Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Progress in Neurobiology 2005, 75:207-246.
58. Chong Z.Z., Li F., Maiese K. Attempted cell cycle induction in post-mitotic neurons occurs in early and late apoptotic programs through Rb, E2F1, and caspase 3. Current Neurovascular Research 2006, 3:25-39.
59. Chong Z.Z., Li F., Maiese K. Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signalling 2007, 19:1150-1162.
60. Chong Z.Z., Li F., Maiese K. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. International Journal of Molecular Medicine 2007, 19:263-272.
61. Chong Z.Z., Lin S.H., Kang J.Q., Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. Journal of Neuroscience Research 2003, 71:659-669.
62. Chong Z.Z., Lin S.H., Kang J.Q., Maiese K. The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. Cellular and Molecular Neurobiology 2003, 23:561-578.
63. Chong Z.Z., Lin S.H., Li F., Maiese K. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through Akt, Bad, PARP, and mitochondrial associated " anti-apoptotic" pathways. Current Neurovascular Research 2005, 2:271-285.
64. Chong Z.Z., Lin S.H., Maiese K. The NAD+ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. Journal of Cerebral Blood Flow & Metabolism 2004, 24:728-743.
65. Chong Z.Z., Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histology and Histopathology 2007, 22:1251-1267.
66. Chong Z.Z., Shang Y.C., Hou J., Maiese K. Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. Oxidative Medicine and Cellular Longevity 2010, 3:153-165.
67. Chong Z.Z., Shang Y.C., Maiese K. Cardiovascular disease and mTOR signaling. Trends in Cardiovascular Medicine 2011, 21:151-155.
68. Chong Z.Z., Shang Y.C., Wang S., Maiese K. SIRT1: New avenues of discovery for disorders of oxidative stress. Expert Opinion on Therapeutic Targets 2012, 16:167-178.
69. Chong Z.Z., Shang Y.C., Zhang L., Wang S., Maiese K. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxidative Medicine and Cellular Longevity 2010, 3:374-391.
70. Chong Z.Z., Wang S., Shang Y.C., Maiese K. Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiology 2012, 8:89-100.
71. Chung C.Y., Park Y.L., Song Y.A., Myung E., Kim K.Y., Lee G.H., Ki H.S., Park K.J., Cho S.B., Lee W.S., Jung Y.D., Kim K.K., Joo Y.E. Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells. Digestive Diseases and Sciences 2012, 57:371-380.
72. Codeluppi S., Svensson C.I., Hefferan M.P., Valencia F., Silldorff M.D., Oshiro M., Marsala M., Pasquale E.B. The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord. Journal of Neuroscience 2009, 29:1093-1104.
73. Cota D., Proulx K., Smith K.A., Kozma S.C., Thomas G., Woods S.C., Seeley R.J. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312:927-930.
74. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. Lancet 2008, 372:657-668.
75. Curran M.P. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatric Drugs 2012, 14:51-60.
76. Czene S., Tiback M., Harms-Ringdahl M. pH-dependent DNA cleavage in permeabilized human fibroblasts. Biochemical Journal 1997, 323:337-341.
77. Dada S., Demartines N., Dormond O. mTORC2 regulates PGE2-mediated endothelial cell survival and migration. Biochemical and Biophysical Research Communication 2008, 372:875-879.
78. Dan H.C., Adli M., Baldwin A.S. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Research 2007, 67:6263-6269.
79. Das J., Ghosh J., Manna P., Sil P.C. Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via up-regulation of PI3-K/Akt and inhibition of p53, p38-JNK. Biochemical Pharmacology 2011, 81:891-909.
80. Dasgupta B., Yi Y., Chen D.Y., Weber J.D., Gutmann D.H. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Research 2005, 65:2755-2760.
81. De Simone R., Ajmone-Cat M.A., Minghetti L. Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction. Molecular Neurobiology 2004, 29:197-212.
82. Deblon N., Bourgoin L., Veyrat-Durebex C., Peyrou M., Vinciguerra M., Caillon A., Maeder C., Fournier M., Montet X., Rohner-Jeanrenaud F., Foti M. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. British Journal of Pharmacology 2012, 165:2325-2340.
83. Dello Russo C., Lisi L., Tringali G., Navarra P. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochemical Pharmacology 2009, 78:1242-1251.
84. Deruy E., Gosselin K., Vercamer C., Martien S., Bouali F., Slomianny C., Bertout J., Bernard D., Pourtier A., Abbadie C. MnSOD upregulation induces autophagic programmed cell death in senescent keratinocytes. PLoS One 2010, 5:e12712.
85. DeYoung M.P., Horak P., Sofer A., Sgroi D., Ellisen L.W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Development 2008, 22:239-251.
86. Di Nardo A., Kramvis I., Cho N., Sadowski A., Meikle L., Kwiatkowski D.J., Sahin M. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. Journal of Neuroscience 2009, 29:5926-5937.
87. Dibble C.C., Asara J.M., Manning B.D. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Molecular and Cellular Biology 2009, 29:5657-5670.
88. Dormond O., Madsen J.C., Briscoe D.M. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. Journal of Biological Chemistry 2007, 282:23679-23686.
89. Du Y., Zhang X., Ji H., Liu H., Li S., Li L. Probucol and atorvastatin in combination protect rat brains in MCAO model: upregulating Peroxiredoxin2, Foxo3a and Nrf2 expression. Neuroscience Letters 2012, 509:110-115.
90. Duan S., Skaar J.R., Kuchay S., Toschi A., Kanarek N., Ben-Neriah Y., Pagano M. mTOR generates an auto-amplification loop by triggering the betaTrCP- and CK1alpha-dependent degradation of DEPTOR. Molecular Cell 2011, 44:317-324.
91. Easley C.A., Ben-Yehudah A., Redinger C.J., Oliver S.L., Varum S.T., Eisinger V.M., Carlisle D.L., Donovan P.J., Schatten G.P. mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. Cellular Reprogramming 2010, 12:263-273.
92. Echeverria V., Zeitlin R., Burgess S., Patel S., Barman A., Thakur G., Mamcarz M., Wang L., Sattelle D.B., Kirschner D.A., Mori T., Leblanc R.M., Prabhakar R., Arendash G.W. Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice. Journal of Alzheimers Disease 2011.
93. Eipel C., Hubschmann U., Abshagen K., Wagner K.F., Menger M.D., Vollmar B. Erythropoietin as additive of HTK preservation solution in cold ischemia/reperfusion injury of steatotic livers. Journal of Surgical Research 2012, 173:171-179.
94. Ekim B., Magnuson B., Acosta-Jaquez H.A., Keller J.A., Feener E.P., Fingar D.C. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Molecular and Cellular Biology 2011, 31:2787-2801.
95. Erlich S., Alexandrovich A., Shohami E., Pinkas-Kramarski R. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiology of Disease 2007, 26:86-93.
96. Escobar J., Pereda J., Lopez-Rodas G., Sastre J. Redox signaling and histone acetylation in acute pancreatitis. Free Radical Biology and Medicine 2012, 52:819-837.
97. Faghiri Z., Bazan N.G. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis. Experimental Eye Research 2010, 90:718-725.
98. Fernandez-Martos C.M., Gonzalez-Fernandez C., Gonzalez P., Maqueda A., Arenas E., Rodriguez F.J. Differential expression of wnts after spinal cord contusion injury in adult rats. PLoS ONE 2011, 6:e27000.
99. Fingar D.C., Richardson C.J., Tee A.R., Cheatham L., Tsou C., Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Molecular and Cellular Biology 2004, 24:200-216.
100. Floto R.A., Sarkar S., Perlstein E.O., Kampmann B., Schreiber S.L., Rubinsztein D.C. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages. Autophagy 2007, 3:620-622.
101. Floyd S., Favre C., Lasorsa F.M., Leahy M., Trigiante G., Stroebel P., Marx A., Loughran G., O'Callaghan K., Marobbio C.M., Slotboom D.J., Kunji E.R., Palmieri F., O'Connor R. The insulin-like growth factor-I-mTOR signaling pathway induces the mitochondrial pyrimidine nucleotide carrier to promote cell growth. Molecular Biology of Cell 2007, 18:3545-3555.
102. Fokas E., Yoshimura M., Prevo R., Higgins G., Hackl W., Maira S.M., Bernhard E.J., McKenna W.G., Muschel R.J. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/Mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. Radiation Oncology 2012, 7:48.
103. Fox J.H., Connor T., Chopra V., Dorsey K., Kama J.A., Bleckmann D., Betschart C., Hoyer D., Frentzel S., Difiglia M., Paganetti P., Hersch S.M. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. Molecular Neurodegeneration 2010, 5:26.
104. Frias M.A., Thoreen C.C., Jaffe J.D., Schroder W., Sculley T., Carr S.A., Sabatini D.M. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Current Biology 2006, 16:1865-1870.
105. Galan-Moya E.M., Le Guelte A., Lima Fernandes E., Thirant C., Dwyer J., Bidere N., Couraud P.O., Scott M.G., Junier M.P., Chneiweiss H., Gavard J. Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Reports 2011, 12:470-476.
106. Gangloff Y.G., Mueller M., Dann S.G., Svoboda P., Sticker M., Spetz J.F., Um S.H., Brown E.J., Cereghini S., Thomas G., Kozma S.C. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Molecular and Cellular Biology 2004, 24:9508-9516.
107. Gao D., Inuzuka H., Tan M.K., Fukushima H., Locasale J.W., Liu P., Wan L., Zhai B., Chin Y.R., Shaik S., Lyssiotis C.A., Gygi S.P., Toker A., Cantley L.C., Asara J.M., Harper J.W., Wei W. mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Molecular Cell 2011, 44:290-303.
108. Garcia-Martinez J.M., Alessi D.R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochemical Journal 2008, 416:375-385.
109. Ghosh N., Ghosh R., Mandal S.C. Antioxidant protection: a promising therapeutic intervention in neurodegenerative disease. Free Radical Research 2011, 45:888-905.
110. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Development 1998, 12:502-513.
111. Glidden E.J., Gray L.G., Vemuru S., Li D., Harris T.E., Mayo M.W. Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein. Journal of Biological Chemistry 2012, 287:581-588.
112. Goffus A.M., Anderson G.D., Hoane M. Sustained delivery of nicotinamide limits cortical injury and improves functional recovery following traumatic brain injury. Oxidative Medicine and Cellular Longevity 2010, 3:145-152.
113. Good D.W., George T., Watts B.A. Nerve growth factor inhibits Na+/H+ exchange and formula absorption through parallel phosphatidylinositol 3-kinase-mTOR and ERK pathways in thick ascending limb. Journal of Biological Chemistry 2008, 283:26602-26611.
114. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. Journal of Neurochemistry 2005, 93:105-117.
115. Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Developmental Cell 2006, 11:859-871.
116. Gulhati P., Bowen K.A., Liu J., Stevens P.D., Rychahou P.G., Chen M., Lee E.Y., Weiss H.L., O'Connor K.L., Gao T., Evers B.M. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Research 2011, 71:3246-3256.
117. Gumy L.F., Tan C.L., Fawcett J.W. The role of local protein synthesis and degradation in axon regeneration. Experimental Neurology 2010, 223:28-37.
118. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Molecular Cell 2008, 30:214-226.
119. Han J., Shi S., Min L., Wu T., Xia W., Ying W. NAD(+) treatment induces delayed autophagy in Neuro2a cells partially by increasing oxidative stress. Neurochemical Research 2011, 36:2270-2277.
120. Han J., Wang B., Xiao Z., Gao Y., Zhao Y., Zhang J., Chen B., Wang X., Dai J. Mammalian target of rapamycin (mTOR) is involved in the neuronal differentiation of neural progenitors induced by insulin. Molecular and Cellular Neuroscience 2008, 39:118-124.
121. Hansel D.E., Platt E., Orloff M., Harwalker J., Sethu S., Hicks J.L., De Marzo A., Steinle R.E., Hsi E.D., Theodorescu D., Ching C.B., Eng C. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. American Journal of Pathology 2010, 176:3062-3072.
122. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110:177-189.
123. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downes C.P., Lamb R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. Journal of Cell Biology 2004, 166:213-223.
124. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
125. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253:905-909.
126. Herbas M.S., Ueta Y.Y., Ishibashi K., Suzuki H. Expression of erythropoietic cytokines in alpha-tocopherol transfer protein knockout mice with murine malaria infection. Parasitology Research 2011, 109:1243-1250.
127. Hernandez G., Lal H., Fidalgo M., Guerrero A., Zalvide J., Force T., Pombo C.M. A novel cardioprotective p38-MAPK/mTOR pathway. Experimental Cell Research 2011, 317:2938-2949.
128. Hernandez-Negrete I., Carretero-Ortega J., Rosenfeldt H., Hernandez-Garcia R., Calderon-Salinas J.V., Reyes-Cruz G., Gutkind J.S., Vazquez-Prado J. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. Journal of Biological Chemistry 2007, 282:23708-23715.
129. Heublein S., Kazi S., Ogmundsdottir M.H., Attwood E.V., Kala S., Boyd C.A., Wilson C., Goberdhan D.C. Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation. Oncogene 2010, 29:4068-4079.
130. Hofbauer G.F., Marcollo-Pini A., Corsenca A., Kistler A.D., French L.E., Wuthrich R.P., Serra A.L. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. The British Journal of Dermatology 2008, 159:473-475.
131. Holmes G.L., Stafstrom C.E. Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia 2007, 48:617-630.
132. Holz M.K., Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. Journal of Biological Chemistry 2005, 280:26089-26093.
133. Hong J.R., Lin G.H., Lin C.J., Wang W.P., Lee C.C., Lin T.L., Wu J.L. Phosphatidylserine receptor is required for the engulfment of dead apoptotic cells and for normal embryonic development in zebrafish. Development 2004, 131:5417-5427.
134. Hosokawa N., Sasaki T., Iemura S., Natsume T., Hara T., Mizushima N. Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy 2009, 5:973-979.
135. Hou G., Xue L., Lu Z., Fan T., Tian F., Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Letters 2007, 253:236-248.
136. Hou J., Chong Z.Z., Shang Y.C., Maiese K. Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Current Neurovascular Research 2010, 7:95-112.
137. Hou J., Chong Z.Z., Shang Y.C., Maiese K. FoxO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Molecular and Cellular Endocrinology 2010, 321:194-206.
138. Hou J., Wang S., Shang Y.C., Chong Z.Z., Maiese K. Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Current Neurovascular Research 2011, 8:220-235.
139. Hresko R.C., Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. Journal of Biological Chemistry 2005, 280:40406-40416.
140. Hu L.Y., Sun Z.G., Wen Y.M., Cheng G.Z., Wang S.L., Zhao H.B., Zhang X.R. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats. Neuroscience 2010, 169:1046-1062.
141. Huang J., Dibble C.C., Matsuzaki M., Manning B.D. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Molecular and Cellular Biology 2008, 28:4104-4115.
142. Huang J., Wu S., Wu C.L., Manning B.D. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Research 2009, 69:6107-6114.
143. Huang J., Zhang Y., Bersenev A., O'Brien W.T., Tong W., Emerson S.G., Klein P.S. Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. Journal of Clinical Investigation 2009, 119:3519-3529.
144. Huang X., McMahon J., Huang Y. Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy. Neuroscience 2012.
145. Hwang S.K., Kim H.H. The functions of mTOR in ischemic diseases. BMB Reports 2011, 44:506-511.
146. Hyrskyluoto A., Reijonen S., Kivinen J., Lindholm D., Korhonen L. GADD34 mediates cytoprotective autophagy in mutant huntingtin expressing cells via the mTOR pathway. Experimental Cell Research 2012, 318:33-42.
147. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. Embo Journal 2008, 27:2432-2443.
148. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biology 2002, 4:648-657.
149. Inoki K., Ouyang H., Zhu T., Lindvall C., Wang Y., Zhang X., Yang Q., Bennett C., Harada Y., Stankunas K., Wang C.Y., He X., MacDougald O.A., You M., Williams B.O., Guan K.L. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006, 126:955-968.
150. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
151. Jaber N., Dou Z., Chen J.S., Catanzaro J., Jiang Y.P., Ballou L.M., Selinger E., Ouyang X., Lin R.Z., Zhang J., Zong W.X. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proceedings of the National Academy of Sciences United States of America 2012, 109:2003-2008.
152. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
153. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biology 2004, 6:1122-1128.
154. James M.F., Stivison E., Beauchamp R., Han S., Li H., Wallace M.R., Gusella J.F., Stemmer-Rachamimov A.O., Ramesh V. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Molecular Cancer Research 2012.
155. Janku F., Wheler J.J., Westin S.N., Moulder S.L., Naing A., Tsimberidou A.M., Fu S., Falchook G.S., Hong D.S., Garrido-Laguna I., Luthra R., Lee J.J., Lu K.H., Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. Journal of Clinical Oncology 2012, 30:777-782.
156. Jastrzebski K., Hannan K.M., Tchoubrieva E.B., Hannan R.D., Pearson R.B. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 2007, 25:209-226.
157. Jayaram H.N., Kusumanchi P., Yalowitz J.A. NMNAT expression and its relation to NAD metabolism. Current Medicinal Chemistry 2011, 18:1962-1972.
158. Jeong J.K., Moon M.H., Bae B.C., Lee Y.J., Seol J.W., Kang H.S., Kim J.S., Kang S.J., Park S.Y. Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. Neuroscience Research 2012, 73:99-105.
159. Jiang Y.L., Ning Y., Ma X.L., Liu Y.Y., Wang Y., Zhang Z., Shan C.X., Xu Y.D., Yin L.M., Yang Y.Q. Alteration of the proteome profile of the pancreas in diabetic rats induced by streptozotocin. International Journal of Molecular Medicine 2011, 28:153-160.
160. Johannessen C.M., Johnson B.W., Williams S.M., Chan A.W., Reczek E.E., Lynch R.C., Rioth M.J., McClatchey A., Ryeom S., Cichowski K. TORC1 is essential for NF1-associated malignancies. Current Biology 2008, 18:56-62.
161. Jozwiak J., Kotulska K., Lojek M., Galus R., Jozwiak S., Polnik D., Wlodarski P.K. Fibroblasts from normal skin of a tuberous sclerosis patient show upregulation of mTOR pathway. The American Journal of Dermatopathology 2009, 31:68-70.
162. Julien L.A., Carriere A., Moreau J., Roux P.P. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Molecular and Cellular Biology 2010, 30:908-921.
163. Jung C.H., Jun C.B., Ro S.H., Kim Y.M., Otto N.M., Cao J., Kundu M., Kim D.H. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Molecular Biology of Cell 2009, 20:1992-2003.
164. Kabeya Y., Kamada Y., Baba M., Takikawa H., Sasaki M., Ohsumi Y. Atg17 functions in cooperation with Atg1 and Atg13 in yeast autophagy. Molecular Biology of Cell 2005, 16:2544-2553.
165. Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 2005, 1:15-25.
166. Kamada Y., Funakoshi T., Shintani T., Nagano K., Ohsumi M., Ohsumi Y. Tor-mediated induction of autophagy via an Apg1 protein kinase complex. Journal of Cell Biology 2000, 150:1507-1513.
167. Kang J.Q., Chong Z.Z., Maiese K. Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. Journal of Neuroscience Research 2003, 74:37-51.
168. Kang J.Q., Chong Z.Z., Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Molecular Pharmacology 2003, 64:557-569.
169. Karlsson E., Waltersson M.A., Bostner J., Perez-Tenorio G., Olsson B., Hallbeck A.L., Stal O. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 2011, 50:775-787.
170. Kato S., Aoyama M., Kakita H., Hida H., Kato I., Ito T., Goto T., Hussein M.H., Sawamoto K., Togari H., Asai K. Endogenous erythropoietin from astrocyte protects the oligodendrocyte precursor cell against hypoxic and reoxygenation injury. Journal of Neuroscience Research 2011, 89:1566-1574.
171. Kawamoto E.M., Gleichmann M., Yshii L.M., Lima Lde S., Mattson M.P., Scavone C. Effect of activation of canonical Wnt signaling by the Wnt-3a protein on the susceptibility of PC12 cells to oxidative and apoptotic insults. Brazilian Journal of Medical and Biological Research 2012, 45:58-67.
172. Khan M.M., Ahmad A., Ishrat T., Khan M.B., Hoda M.N., Khuwaja G., Raza S.S., Khan A., Javed H., Vaibhav K., Islam F. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Research 2010, 1328:139-151.
173. Kigerl K.A., Ankeny D.P., Garg S.K., Wei P., Guan Z., Lai W., McTigue D.M., Banerjee R., Popovich P.G. System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo. Experimental Neurology 2012, 233:333-341.
174. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
175. Kim D.H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V., Erdjument-Bromage H., Tempst P., Sabatini D.M. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Molecular Cell 2003, 11:895-904.
176. Kim H., Choi J., Ryu J., Park S.G., Cho S., Park B.C., Lee do H. Activation of autophagy during glutamate-induced HT22 cell death. Biochemical and Biophysical Research Communication 2009, 388:339-344.
177. Kim J., Jung Y., Sun H., Joseph J., Mishra A., Shiozawa Y., Wang J., Krebsbach P.H., Taichman R.S. Erythropoietin mediated bone formation is regulated by mTOR signaling. Journal of Cellular Biochemistry 2012, 113:220-228.
178. Koh P.O. Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway. Neuroscience Letters 2008, 444:74-78.
179. Koh P.O. Nicotinamide attenuates the decrease of astrocytic phosphoprotein PEA-15 in focal cerebral ischemic injury. Journal of Veterinary Medical Science 2012, 74:377-380.
180. Kook Y.H., Ka M., Um M. Neuroprotective cytokines repress PUMA induction in the 1-methyl-4-phenylpyridinium (MPP(+)) model of Parkinson's disease. Biochemical and Biophysical Research Communication 2011, 411:370-374.
181. Koren I., Reem E., Kimchi A. DAP1, a novel substrate of mTOR, negatively regulates autophagy. Current Biology 2010, 20:1093-1098.
182. Kovacina K.S., Park G.Y., Bae S.S., Guzzetta A.W., Schaefer E., Birnbaum M.J., Roth R.A. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. Journal of Biological Chemistry 2003, 278:10189-10194.
183. Kuroyanagi H., Yan J., Seki N., Yamanouchi Y., Suzuki Y., Takano T., Muramatsu M., Shirasawa T. Human ULK1, a novel serine/threonine kinase related to UNC-51 kinase of Caenorhabditis elegans: cDNA cloning, expression, and chromosomal assignment. Genomics 1998, 51:76-85.
184. Kuypers N.J., Hoane M.R. Pyridoxine administration improves behavioral and anatomical outcome after unilateral contusion injury in the rat. Journal of Neurotrauma 2010, 27:1275-1282.
185. L'Episcopo F., Tirolo C., Testa N., Caniglia S., Morale M.C., Deleidi M., Serapide M.F., Pluchino S., Marchetti B. Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of parkinson's disease involves cross talk between inflammatory and wnt/beta-catenin signaling pathways: functional consequences for neuroprotection and repair. Journal of Neuroscience 2012, 32:2062-2085.
186. Lafay-Chebassier C., Paccalin M., Page G., Barc-Pain S., Perault-Pochat M.C., Gil R., Pradier L., Hugon J. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. Journal of Neurochemistry 2005, 94:215-225.
187. Lafay-Chebassier C., Perault-Pochat M.C., Page G., Rioux Bilan A., Damjanac M., Pain S., Houeto J.L., Gil R., Hugon J. The immunosuppressant rapamycin exacerbates neurotoxicity of Abeta peptide. Journal of Neuroscience Research 2006, 84:1323-1334.
188. Land S.C., Tee A.R. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. Journal of Biological Chemistry 2007, 282:20534-20543.
189. Lappas M., Permezel M. The anti-inflammatory and antioxidative effects of nicotinamide, a vitamin B(3) derivative, are elicited by FoxO3 in human gestational tissues: implications for preterm birth. The Journal of Nutritional Biochemistry 2011, 22:1195-1201.
190. Le X.F., Mao W., Lu Z., Carter B.Z., Bast R.C. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 2010.
191. Lee D.F., Kuo H.P., Chen C.T., Hsu J.M., Chou C.K., Wei Y., Sun H.L., Li L.Y., Ping B., Huang W.C., He X., Hung J.Y., Lai C.C., Ding Q., Su J.L., Yang J.Y., Sahin A.A., Hortobagyi G.N., Tsai F.J., Tsai C.H., Hung M.C. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130:440-455.
192. Lee G., Pollard H.B., Arispe N. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 2002, 23:1249-1263.
193. Lee S.T., Chu K., Park J.E., Jung K.H., Jeon D., Lim J.Y., Lee S.K., Kim M., Roh J.K. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models. Journal of Neurochemistry 2012, 120:115-124.
194. Lehtinen M.K., Tegelberg S., Schipper H., Su H., Zukor H., Manninen O., Kopra O., Joensuu T., Hakala P., Bonni A., Lehesjoki A.E. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy EPM1. Journal of Neuroscience 2009, 29:5910-5915.
195. Leuner K., Hauptmann S., Abdel-Kader R., Scherping I., Keil U., Strosznajder J.B., Eckert A., Muller W.E. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease?. Antioxidants & Redox Signaling 2007, 9:1659-1675.
196. Li F., Chong Z.Z., Maiese K. Vital elements of the wnt-frizzled signaling pathway in the nervous system. Current Neurovascular Research 2005, 2:331-340.
197. Li F., Chong Z.Z., Maiese K. Cell life versus cell longevity: the mysteries surrounding the NAD(+) precursor nicotinamide. Current Medicinal Chemistry 2006, 13:883-895.
198. Li F., Chong Z.Z., Maiese K. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Current Neurovascular Research 2006, 3:187-201.
199. Li F., Chong Z.Z., Maiese K. Winding through the WNT pathway during cellular development and demise. Histology and Histopathology 2006, 21:103-124.
200. Li L., Kim E., Yuan H., Inoki K., Goraksha-Hicks P., Schiesher R.L., Neufeld T.P., Guan K.L. Regulation of mTORC1 by the Rab and Arf GTPases. Journal of Biological Chemistry 2010, 285:19705-19709.
201. Li X., Alafuzoff I., Soininen H., Winblad B., Pei J.J. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. The FEBS Journal 2005, 272:4211-4220.
202. Lin S.H., Chong Z.Z., Maiese K. Cell cycle induction in post-mitotic neurons proceeds in concert with the initial phase of programmed cell death in rat. Neuroscience Letters 2001, 310:173-177.
203. Lin S.H., Vincent A., Shaw T., Maynard K.I., Maiese K. Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death. Journal of Cerebral Blood Flow & Metabolism 2000, 20:1380-1391.
204. Liu G., Detloff M.R., Miller K.N., Santi L., Houle J.D. Exercise modulates microRNAs that affect the PTEN/mTOR pathway in rats after spinal cord injury. Experimental Neurology 2012, 233:447-456.
205. Liu K., Liu C., Shen L., Shi J., Zhang T., Zhou Y., Zhou L., Sun X. Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice. Neurochemistry International 2011.
206. Liu K., Lu Y., Lee J.K., Samara R., Willenberg R., Sears-Kraxberger I., Tedeschi A., Park K.K., Jin D., Cai B., Xu B., Connolly L., Steward O., Zheng B., He Z. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nature Neuroscience 2010, 13:1075-1081.
207. Liu T., Jin H., Sun Q.R., Xu J.H., Hu H.T. The neuroprotective effects of tanshinone IIA on beta-amyloid-induced toxicity in rat cortical neurons. Neuropharmacology 2010, 59:595-604.
208. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Molecular Cell 2002, 10:457-468.
209. Luo S., Rubinsztein D.C. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death & Differentiation 2010, 17:268-277.
210. Ma J., Li M., Hock J., Yu X. Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1. Journal of Orthopaedic Research 2012, 30:144-152.
211. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
212. Ma T., Hoeffer C.A., Capetillo-Zarate E., Yu F., Wong H., Lin M.T., Tampellini D., Klann E., Blitzer R.D., Gouras G.K. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One 2010, 5.
213. Magri L., Cambiaghi M., Cominelli M., Alfaro-Cervello C., Cursi M., Pala M., Bulfone A., Garcia-Verdugo J.M., Leocani L., Minicucci F., Poliani P.L., Galli R. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions. Cell Stem Cell 2011, 9:447-462.
214. Maiese K. Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomedicine & Pharmacotherapy 2008, 62:218-232.
215. Maiese K. The many facets of cell injury: angiogenesis to autophagy. Current Neurovascular Research 2012, 9:1-2.
216. Maiese K., Chong Z.Z. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends in Pharmacological Sciences 2003, 24:228-232.
217. Maiese K., Chong Z.Z. Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restorative Neurology and Neuroscience 2004, 22:87-104.
218. Maiese K., Chong Z.Z., Hou J., Shang Y.C. Erythropoietin and oxidative stress. Current Neurovascular Research 2008, 5:125-142.
219. Maiese K., Chong Z.Z., Hou J., Shang Y.C. New strategies for Alzheimer's disease and cognitive impairment. Oxidative Medicine and Cellular Longevity 2009, 2:279-289.
220. Maiese K., Chong Z.Z., Hou J., Shang Y.C. The vitamin nicotinamide: translating nutrition into clinical care. Molecules 2009, 14:3446-3485.
221. Maiese K., Chong Z.Z., Hou J., Shang Y.C. Oxidative stress: biomarkers and novel therapeutic pathways. Experimental Gerontology 2010, 45:217-234.
222. Maiese K., Chong Z.Z., Li F., Shang Y.C. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Progress in Neurobiology 2008, 85:194-213.
223. Maiese K., Chong Z.Z., Shang Y.C. Mechanistic insights into diabetes mellitus and oxidative stress. Current Medicinal Chemistry 2007, 14:1729-1738.
224. Maiese K., Chong Z.Z., Shang Y.C. " Sly as a FOXO": New paths with Forkhead signaling in the brain. Current Neurovascular Research 2007, 4:295-302.
225. Maiese K., Chong Z.Z., Shang Y.C. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends in Molecular Medicine 2008, 14:219-227.
226. Maiese K., Chong Z.Z., Shang Y.C. Raves and risks for erythropoietin. Cytokine & Growth Factor Reviews 2008, 19:145-155.
227. Maiese K., Chong Z.Z., Shang Y.C., Hou J. Clever cancer strategies with FoxO transcription factors. Cell Cycle 2008, 7:3829-3839.
228. Maiese K., Chong Z.Z., Shang Y.C., Hou J. Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling?. Expert Opinion on Therapeutic Targets 2008, 12:905-916.
229. Maiese K., Chong Z.Z., Shang Y.C., Hou J. Therapeutic promise and principles: metabotropic glutamate receptors. Oxidative Medicine and Cellular Longevity 2008, 1:1-14.
230. Maiese K., Chong Z.Z., Shang Y.C., Hou J. A " FOXO" in sight: targeting Foxo proteins from conception to cancer. Medical Research Review 2009, 29:395-418.
231. Maiese K., Chong Z.Z., Shang Y.C., Hou J. Novel avenues of drug discovery and biomarkers for diabetes mellitus. Journal of Clinical Pharmacology 2011, 51:128-152.
232. Maiese K., Chong Z.Z., Shang Y.C., Wang S. Translating cell survival and cell longevity into treatment strategies with SIRT1. Romanian Journal of Morphology and Embryology 2011, 52:1173-1185.
233. Maiese K., Hou J., Chong Z.Z., Shang Y.C. Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorldJournal 2009, 9:1072-1104.
234. Maiese K., Hou J., Chong Z.Z., Shang Y.C. A fork in the path: developing therapeutic inroads with FoxO proteins. Oxidative Medicine and Cellular LongevityV 2 2009, 119-129.
235. Maiese K., Li F., Chong Z.Z. Erythropoietin in the brain: can the promise to protect be fulfilled?. Trends in Pharmacological Sciences 2004, 25:577-583.
236. Maiese K., Li F., Chong Z.Z. New avenues of exploration for erythropoietin. Jama 2005, 293:90-95.
237. Maiese K., Li F., Chong Z.Z., Shang Y.C. The Wnt signaling pathway: aging gracefully as a protectionist?. Pharmacology & Therapeutics 2008, 118:58-81.
238. Maiese K., Morhan S.D., Chong Z.Z. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Current Neurovascular Research 2007, 4:63-71.
239. Majd S., Zarifkar A., Rastegar K., Takhshid M.A. Different fibrillar Abeta 1-42 concentrations induce adult hippocampal neurons to reenter various phases of the cell cycle. Brain Research 2008, 1218:224-229.
240. Majumder S., Richardson A., Strong R., Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS ONE 2011, 6:e25416.
241. Malagelada C., Jin Z.H., Jackson-Lewis V., Przedborski S., Greene L.A. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. Journal of Neuroscience 2010, 30:1166-1175.
242. Malagelada C., Lopez-Toledano M.A., Willett R.T., Jin Z.H., Shelanski M.L., Greene L.A. RTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migration. Journal of Neuroscience 2011, 31:3186-3196.
243. Malagelada C., Ryu E.J., Biswas S.C., Jackson-Lewis V., Greene L.A. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. Journal of Neuroscience 2006, 26:9996-10005.
244. Mancini D., Pinney S., Burkhoff D., LaManca J., Itescu S., Burke E., Edwards N., Oz M., Marks A.R. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48-53.
245. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Molecular Cell 2002, 10:151-162.
246. Masri J., Bernath A., Martin J., Jo O.D., Vartanian R., Funk A., Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Research 2007, 67:11712-11720.
247. Maycotte P., Guemez-Gamboa A., Moran J. Apoptosis and autophagy in rat cerebellar granule neuron death: Role of reactive oxygen species. Journal of Neuroscience Research 2010, 88:73-85.
248. Meikle L., Pollizzi K., Egnor A., Kramvis I., Lane H., Sahin M., Kwiatkowski D.J. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. Journal of Neuroscience 2008, 28:5422-5432.
249. Miriuka S.G., Rao V., Peterson M., Tumiati L., Delgado D.H., Mohan R., Ramzy D., Stewart D., Ross H.J., Waddell T.K. mTOR inhibition induces endothelial progenitor cell death. American Journal of Transplantation 2006, 6:2069-2079.
250. Mounier C., Dumas V., Posner B.I. Regulation of hepatic insulin-like growth factor-binding protein-1 gene expression by insulin: central role for mammalian target of rapamycin independent of forkhead box O proteins. Endocrinology 2006, 147:2383-2391.
251. Murakami M., Ichisaka T., Maeda M., Oshiro N., Hara K., Edenhofer F., Kiyama H., Yonezawa K., Yamanaka S. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Molecular and Cellular Biology 2004, 24:6710-6718.
252. Nascimento E.B., Snel M., Guigas B., van der Zon G.C., Kriek J., Maassen J.A., Jazet I.M., Diamant M., Ouwens D.M. Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cell Signalling 2010, 22:961-967.
253. Nellist M., Burgers P.C., van den Ouweland A.M., Halley D.J., Luider T.M. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex. Biochemical and Biophysical Research Communication 2005, 333:818-826.
254. Nopparat C., Porter J.E., Ebadi M., Govitrapong P. The mechanism for the neuroprotective effect of melatonin against methamphetamine-induced autophagy. Journal of Pineal Research 2010.
255. O'Dell C.M., Das A., Wallace G.t., Ray S.K., Banik N.L. Understanding the basic mechanisms underlying seizures in mesial temporal lobe epilepsy and possible therapeutic targets: a review. Journal of Neuroscience Research 2012, 90:913-924.
256. Ogura Y., Iemitsu M., Naito H., Kakigi R., Kakehashi C., Maeda S., Akema T. Single bout of running exercise changes LC3-II expression in rat cardiac muscle. Biochemical and Biophysical Research Communication 2011, 414:756-760.
257. Okaji Y., Tashiro Y., Gritli I., Nishida C., Sato A., Ueno Y., Del Canto Gonzalez S., Ohki-Koizumi M., Akiyama H., Nakauchi H., Hattori K., Heissig B. Plasminogen deficiency attenuates postnatal erythropoiesis in male C57BL/6 mice through decreased activity of the LH-testosterone axis. Experimental Hematology 2012, 40:143-154.
258. Oshiro N., Takahashi R., Yoshino K., Tanimura K., Nakashima A., Eguchi S., Miyamoto T., Hara K., Takehana K., Avruch J., Kikkawa U., Yonezawa K. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. Journal of Biological Chemistry 2007, 282:20329-20339.
259. Paccalin M., Pain-Barc S., Pluchon C., Paul C., Besson M.N., Carret-Rebillat A.S., Rioux-Bilan A., Gil R., Hugon J. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2006, 22:320-326.
260. Park K.H., Choi N.Y., Koh S.H., Park H.H., Kim Y.S., Kim M.J., Lee S.J., Yu H.J., Lee K.Y., Lee Y.J., Kim H.T. L-DOPA neurotoxicity is prevented by neuroprotective effects of erythropoietin. Neurotoxicology 2011, 32:879-887.
261. Park K.K., Liu K., Hu Y., Smith P.D., Wang C., Cai B., Xu B., Connolly L., Kramvis I., Sahin M., He Z. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008, 322:963-966.
262. Parsons R.G., Gafford G.M., Helmstetter F.J. Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons. Journal of Neuroscience 2006, 26:12977-12983.
263. Pastor M.D., Garcia-Yebenes I., Fradejas N., Perez-Ortiz J.M., Mora-Lee S., Tranque P., Moro M.A., Pende M., Calvo S. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. Journal of Biological Chemistry 2009, 284:22067-22078.
264. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., Packer M., Schneider M.D., Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
265. Pavel M.E., Hainsworth J.D., Baudin E., Peeters M., Horsch D., Winkler R.E., Klimovsky J., Lebwohl D., Jehl V., Wolin E.M., Oberg K., Van Cutsem E., Yao J.C. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012.
266. Pearce L.R., Huang X., Boudeau J., Pawlowski R., Wullschleger S., Deak M., Ibrahim A.F., Gourlay R., Magnuson M.A., Alessi D.R. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochemical Journal 2007, 405:513-522.
267. Pearce L.R., Sommer E.M., Sakamoto K., Wullschleger S., Alessi D.R. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochemical Journal 2011, 436:169-179.
268. Pei J.J., Hugon J. mTOR-dependent signalling in Alzheimer's disease. Journal of Cellular and Molecular Medicine 2008, 12:2525-2532.
269. Perek-Polnik M., Jozwiak S., Jurkiewicz E., Perek D., Kotulska K. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. European Journal of Paediatric Neurology 2012, 16:83-85.
270. Peterson R.T., Beal P.A., Comb M.J., Schreiber S.L. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. Journal of Biological Chemistry 2000, 275:7416-7423.
271. Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S., Sabatini D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
272. Popescu N.I., Lupu C., Lupu F. Extracellular protein disulfide isomerase regulates coagulation on endothelial cells through modulation of phosphatidylserine exposure. Blood 2010, 116:993-1001.
273. Potter C.J., Pedraza L.G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nature Cell Biology 2002, 4:658-665.
274. Qin A.P., Liu C.F., Qin Y.Y., Hong L.Z., Xu M., Yang L., Liu J., Qin Z.H., Zhang H.L. Autophagy was activated in injured astrocytes and mildly decreased cell survival following glucose and oxygen deprivation and focal cerebral ischemia. Autophagy 2010, 6:738-753.
275. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genetics 2004, 36:585-595.
276. Recchia A.G., Musti A.M., Lanzino M., Panno M.L., Turano E., Zumpano R., Belfiore A., Ando S., Maggiolini M. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. International Journal of Biochemistry & Cell Biology 2009, 41:603-614.
277. Reynolds T.H.t, Bodine S.C., Lawrence J.C. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. Journal of Biological Chemistry 2002, 277:17657-17662.
278. Rjiba-Touati K., Ayed-Boussema I., Belarbia A., Achour A., Bacha H. Recombinant human erythropoietin prevents cisplatin-induced genotoxicity in rat liver and heart tissues via an antioxidant process. Drug and Chemical Toxicology 2012, 35:134-140.
279. Roscic A., Baldo B., Crochemore C., Marcellin D., Paganetti P. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. Journal of Neurochemistry 2011, 119:398-407.
280. Rosner M., Fuchs C., Siegel N., Valli A., Hengstschlager M. Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. Human Molecular Genetics 2009, 18:3298-3310.
281. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proceedings of the National Academy of Sciences United States of America 2004, 101:13489-13494.
282. Saha A.K., Xu X.J., Lawson E., Deoliveira R., Brandon A.E., Kraegen E.W., Ruderman N.B. Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes 2010, 59:2426-2434.
283. Sales Santos I., da Rocha Tomé A., Saldanha G., Ferreira P., Militão G., de Freitas R. Oxidative stress in the hippocampus during experimental seizures can be ameliorated with the antioxidant ascorbic acid. Oxidative Medicine and Cellular Longevity 2009, 2:23-30.
284. Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S., Sabatini D.M. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141:290-303.
285. Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., Sabatini D.M. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
286. Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., Spooner E., Carr S.A., Sabatini D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Molecular Cell 2007, 25:903-915.
287. Santini E., Heiman M., Greengard P., Valjent E., Fisone G. Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Science Signaling 2009, 2:ra36.
288. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current Biology 2004, 14:1296-1302.
289. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell 2006, 22:159-168.
290. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
291. Sato A., Sunayama J., Matsuda K., Tachibana K., Sakurada K., Tomiyama A., Kayama T., Kitanaka C. Regulation of neural stem/progenitor cell maintenance by PI3K and mTOR. Neuroscience Letters 2010, 470:115-120.
292. Sato T., Nakashima A., Guo L., Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. Journal of Biological Chemistry 2009, 284:12783-12791.
293. Schneider A., Younis R.H., Gutkind J.S. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 2008, 10:1295-1302.
294. Schutters K., Reutelingsperger C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis 2010, 15:1072-1082.
295. Scott R.C., Juhasz G., Neufeld T.P. Direct induction of autophagy by Atg1 inhibits cell growth and induces apoptotic cell death. Current Biology 2007, 17:1-11.
296. Sehgal S.N., Baker H., Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. Journal of Antibiotics (Tokyo) 1975, 28:727-732.
297. Selman C., Tullet J.M., Wieser D., Irvine E., Lingard S.J., Choudhury A.I., Claret M., Al-Qassab H., Carmignac D., Ramadani F., Woods A., Robinson I.C., Schuster E., Batterham R.L., Kozma S.C., Thomas G., Carling D., Okkenhaug K., Thornton J.M., Partridge L., Gems D., Withers D.J. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.
298. Shan J., Nguyen T.B., Totary-Jain H., Dansky H., Marx S.O., Marks A.R. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proceedings of the National Academy of Sciences United States of America 2008, 105:19006-19011.
299. Shang Y.C., Chong Z.Z., Hou J., Maiese K. The forkhead transcription factor FoxO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Current Neurovascular Research 2009, 6:20-31.
300. Shang Y.C., Chong Z.Z., Hou J., Maiese K. FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Current Neurovascular Research 2009, 6:223-238.
301. Shang Y.C., Chong Z.Z., Hou J., Maiese K. Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. Cell Signalling 2010, 22:1317-1329.
302. Shang Y.C., Chong Z.Z., Wang S., Maiese K. Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia. Current Neurovascular Research 2011, 8:270-285.
303. Shang Y.C., Chong Z.Z., Wang S., Maiese K. Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) 2012, 4:187-201.
304. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., Cantley L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proceedings of the National Academy of Sciences United States of America 2004, 101:3329-3335.
305. Sheng B., Liu J., Li G.H. Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK, HIF and mTOR signaling. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 2012.
306. Shi G.D., OuYang Y.P., Shi J.G., Liu Y., Yuan W., Jia L.S. PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway. Biochemical and Biophysical Research Communication 2011, 404:941-945.
307. Siegel N., Rosner M., Unbekandt M., Fuchs C., Slabina N., Dolznig H., Davies J.A., Lubec G., Hengstschlager M. Contribution of human amniotic fluid stem cells to renal tissue formation depends on mTOR. Human Molecular Genetics 2010, 19:3320-3331.
308. Silva D.F., Esteves A.R., Oliveira C.R., Cardoso S.M. Mitochondria: the common upstream driver of amyloid-beta and tau pathology in Alzheimer's disease. Current Alzheimer Research 2011, 8:563-572.
309. Simao F., Matte A., Matte C., Soares F.M., Wyse A.T., Netto C.A., Salbego C.G. Resveratrol prevents oxidative stress and inhibition of Na(+)K(+)-ATPase activity induced by transient global cerebral ischemia in rats. The Journal of Nutritional Biochemistry 2011.
310. Slipczuk L., Bekinschtein P., Katche C., Cammarota M., Izquierdo I., Medina J.H. BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS One 2009, 4:e6007.
311. Soares M.M., King S.W., Thorpe P.E. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nature Medicine 2008, 14:1357-1362.
312. Sofer A., Lei K., Johannessen C.M., Ellisen L.W. Regulation of mTOR and cell growth in response to energy stress by REDD1. Molecular and Cellular Biology 2005, 25:5834-5845.
313. Soliman G.A., Acosta-Jaquez H.A., Dunlop E.A., Ekim B., Maj N.E., Tee A.R., Fingar D.C. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. Journal of Biological Chemistry 2010, 285:7866-7879.
314. Solling C. Organ-protective and immunomodulatory effects of erythropoietin-an update on recent clinical trials. Basic & Clinical Pharmacology & Toxicology 2011.
315. Spencer B., Potkar R., Trejo M., Rockenstein E., Patrick C., Gindi R., Adame A., Wyss-Coray T., Masliah E. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. Journal of Neuroscience 2009, 29:13578-13588.
316. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010, 5:e9979.
317. Srivastava S., Haigis M.C. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer's and Parkinson's diseases. Current Pharmaceutical Design 2011, 17:3418-3433.
318. Su J., Zhang A., Shi Z., Ma F., Pu P., Wang T., Zhang J., Kang C., Zhang Q. MicroRNA-200a suppresses the Wnt/beta-catenin signaling pathway by interacting with beta-catenin. International Journal of Oncology 2012, 40:1162-1170.
319. Su K.H., Shyue S.K., Kou Y.R., Ching L.C., Chiang A.N., Yu Y.B., Chen C.Y., Pan C.C., Lee T.S. beta Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. Journal of Cell Physiology 2011, 226:3330-3339.
320. Sui L., Wang J., Li B.M. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex. Learning & Memory (Cold Spring Harbor, N. Y.) 2008, 15:762-776.
321. Sun F., Park K.K., Belin S., Wang D., Lu T., Chen G., Zhang K., Yeung C., Feng G., Yankner B.A., He Z. Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature 2011, 480:372-375.
322. Suzen S., Cihaner S.S., Coban T. Synthesis and comparison of antioxidant properties of indole-based melatonin analogue indole amino Acid derivatives. Chemical Biology & Drug Design 2012, 79:76-83.
323. Taga M., Mouton-Liger F., Paquet C., Hugon J. Modulation of oxidative stress and tau phosphorylation by the mTOR activator phosphatidic acid in SH-SY5Y cells. FEBS Letters 2011, 585:1801-1806.
324. Tain L.S., Mortiboys H., Tao R.N., Ziviani E., Bandmann O., Whitworth A.J. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nature Neuroscience 2009, 12:1129-1135.
325. Takahara T., Hara K., Yonezawa K., Sorimachi H., Maeda T. Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. Journal of Biological Chemistry 2006, 281:28605-28614.
326. Takahashi T., Hara K., Inoue H., Kawa Y., Tokunaga C., Hidayat S., Yoshino K., Kuroda Y., Yonezawa K. Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells 2000, 5:765-775.
327. Takei H., Dauser R., Su J., Chintagumpala M., Bhattacharjee M.B., Jones J., Adesina A.M. Anaplastic ganglioglioma arising from a Lhermitte-Duclos-like lesion. Case report. Journal of Neurosurgery 2007, 107:137-142.
328. Talos D.M., Sun H., Zhou X., Fitzgerald E.C., Jackson M.C., Klein P.M., Lan V.J., Joseph A., Jensen F.E. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS ONE 2012, 7:e35885.
329. Talving P., Lustenberger T., Inaba K., Lam L., Mohseni S., Chan L., Demetriades D. Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. Archives of Surgery 2012, 147:251-255.
330. Tang S.J., Reis G., Kang H., Gingras A.C., Sonenberg N., Schuman E.M. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proceedings of the National Academy of Sciences United States of America 2002, 99:467-472.
331. Teng F.Y., Tang B.L. NF-kappaB signaling in neurite growth and neuronal survival. Reviews in the Neurosciences 2010, 21:299-313.
332. Thedieck K., Polak P., Kim M.L., Molle K.D., Cohen A., Jeno P., Arrieumerlou C., Hall M.N. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One 2007, 2:e1217.
333. Tominaga T., Kure S., Narisawa K., Yoshimoto T. Endonuclease activation following focal ischemic injury in the rat brain. Brain Research 1993, 608:21-26.
334. Ullah N., Ullah I., Lee H.Y., Naseer M.I., Seok P.M., Ahmed J., Kim M.O. Protective function of nicotinamide against ketamine-induced apoptotic neurodegeneration in the infant rat brain. Journal of Molecular Neuroscience 2012, 47:67-75.
335. Valli A., Rosner M., Fuchs C., Siegel N., Bishop C.E., Dolznig H., Madel U., Feichtinger W., Atala A., Hengstschlager M. Embryoid body formation of human amniotic fluid stem cells depends on mTOR. Oncogene 2010, 29:966-977.
336. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nature Cell Biology 2007, 9:316-323.
337. Vezina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. Journal of Antibiotics (Tokyo) 1975, 28:721-726.
338. Vigneron F., Dos Santos P., Lemoine S., Bonnet M., Tariosse L., Couffinhal T., Duplaa C., Jaspard-Vinassa B. GSK-3beta at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovascular Research 2011, 90:49-56.
339. Vincent A.M., Maiese K. Nitric oxide induction of neuronal endonuclease activity in programmed cell death. Experimental Cell Research 1999, 246:290-300.
340. Vincent A.M., TenBroeke M., Maiese K. Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. Experimental Neurology 1999, 155:79-94.
341. Vincent A.M., TenBroeke M., Maiese K. Neuronal intracellular pH directly mediates nitric oxide-induced programmed cell death. Journal of Neurobiology 1999, 40:171-184.
342. Vonder Haar C., Anderson G.D., Hoane M.R. Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury. Behavioral Brain Research 2011, 224:311-317.
343. Waltereit R., Welzl H., Dichgans J., Lipp H.P., Schmidt W.J., Weller M. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. Journal of Neurochemistry 2006, 96:407-413.
344. Wang H., Zhang Q., Wen Q., Zheng Y., Philip L., Jiang H., Lin J., Zheng W. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signalling 2012, 24:17-24.
345. Wang J., Sun P., Bao Y., Dou B., Song D., Li Y. Vitamin E renders protection to PC12 cells against oxidative damage and apoptosis induced by single-walled carbon nanotubes. Toxicology In Vitro 2012, 26:32-41.
346. Wang J.Y., Xia Q., Chu K.T., Pan J., Sun L.N., Zeng B., Zhu Y.J., Wang Q., Wang K., Luo B.Y. Severe global cerebral ischemia-induced programmed necrosis of hippocampal CA1 neurons in rat is prevented by 3-methyladenine: a widely used inhibitor of autophagy. Journal of Neuropathology & Experimental Neurology 2011, 70:314-322.
347. Wang L., Harris T.E., Lawrence J.C. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. Journal of Biological Chemistry 2008, 283:15619-15627.
348. Wang L., Harris T.E., Roth R.A., Lawrence J.C. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. Journal of Biological Chemistry 2007, 282:20036-20044.
349. Wang L., Lawrence J.C., Sturgill T.W., Harris T.E. Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. Journal of Biological Chemistry 2009, 284:14693-14697.
350. Wang R.H., Kim H.S., Xiao C., Xu X., Gavrilova O., Deng C.X. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. Journal of Clinical Investigation 2011, 121:4477-4490.
351. Wang S., Chong Z.Z., Shang Y.C., Maiese K. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of beta-catenin during oxidant stress with limited effects upon neuronal autophagy. Current Neurovascular Research 2012, 9:89-99.
352. Wang S., Chong Z.Z., Shang Y.C., Maiese K. Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL. Current Neurovascular Research 2012, 9:20-31.
353. Wang Y., Ding L., Wang X., Zhang J., Han W., Feng L., Sun J., Jin H., Wang X.J. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. American Journal of Translational Research 2012, 4:44-51.
354. Weber J.D., Gutmann D.H. Deconvoluting mTOR biology. Cell Cycle 2012, 11:236-248.
355. Woo S.Y., Kim D.H., Jun C.B., Kim Y.M., Haar E.V., Lee S.I., Hegg J.W., Bandhakavi S., Griffin T.J., Kim D.H. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. Journal of Biological Chemistry 2007, 282:25604-25612.
356. Wu X., Reiter C.E., Antonetti D.A., Kimball S.R., Jefferson L.S., Gardner T.W. Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner. Journal of Biological Chemistry 2004, 279:9167-9175.
357. Xie Q., Hao Y., Tao L., Peng S., Rao C., Chen H., You H., Dong M.Q., Yuan Z. Lysine methylation of FOXO3 regulates oxidative stress-induced neuronal cell death. EMBO Reports 2012, 13:371-377.
358. Xu J.T., Zhao X., Yaster M., Tao Y.X. Expression and distribution of mTOR, p70S6K, 4E-BP1, and their phosphorylated counterparts in rat dorsal root ganglion and spinal cord dorsal horn. Brain Research 2010, 1336:46-57.
359. Xue L., Fletcher G.C., Tolkovsky A.M. Autophagy is activated by apoptotic signalling in sympathetic neurons: an alternative mechanism of death execution. Molecular and Cellular Neuroscience 1999, 14:180-198.
360. Yamada E., Singh R. Mapping autophagy on to your metabolic radar. Diabetes 2012, 61:272-280.
361. Yan J., Kuroyanagi H., Kuroiwa A., Matsuda Y., Tokumitsu H., Tomoda T., Shirasawa T., Muramatsu M. Identification of mouse ULK1, a novel protein kinase structurally related to C. elegans UNC-51. Biochemical and Biophysical Research Communication 1998, 246:222-227.
362. Yan J., Kuroyanagi H., Tomemori T., Okazaki N., Asato K., Matsuda Y., Suzuki Y., Ohshima Y., Mitani S., Masuho Y., Shirasawa T., Muramatsu M. Mouse ULK2, a novel member of the UNC-51-like protein kinases: unique features of functional domains. Oncogene 1999, 18:5850-5859.
363. Yang H., Jin X., Kei Lam C.W., Yan S.K. Oxidative stress and diabetes mellitus. Clinical Chemistry and Laboratory Medicine 2011, 49:1773-1782.
364. Yang Q., Inoki K., Ikenoue T., Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Development 2006, 20:2820-2832.
365. Yoo K.Y., Kwon S.H., Lee C.H., Yan B., Park J.H., Ahn J.H., Choi J.H., Ohk T.G., Cho J.H., Won M.H. FoxO3a changes in pyramidal neurons and expresses in non-pyramidal neurons and astrocytes in the gerbil hippocampal CA1 region after transient cerebral ischemia. Neurochemical Research 2012, 37:588-595.
366. Yu L., McPhee C.K., Zheng L., Mardones G.A., Rong Y., Peng J., Mi N., Zhao Y., Liu Z., Wan F., Hailey D.W., Oorschot V., Klumperman J., Baehrecke E.H., Lenardo M.J. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 2010, 465:942-946.
367. Yu Y., Ren Q.G., Zhang Z.H., Zhou K., Yu Z.Y., Luo X., Wang W. Phospho-Rb mediating cell cycle reentry induces early apoptosis following oxygen-glucose deprivation in rat cortical neurons. Neurochemical Research 2012, 37:503-511.
368. Yuan H., Wan J., Li L., Ge P., Li H., Zhang L. Therapeutic benefits of the group B3 vitamin nicotinamide in mice with lethal endotoxemia and polymicrobial sepsis. Pharmacological Research 2012, 65:328-337.
369. Zeng K.W., Wang X.M., Ko H., Kwon H.C., Cha J.W., Yang H.O. Hyperoside protects primary rat cortical neurons from neurotoxicity induced by amyloid beta-protein via the PI3K/Akt/Bad/Bcl(XL)-regulated mitochondrial apoptotic pathway. European Journal of Pharmacology 2011, 672:45-55.
370. Zeng L.H., Rensing N.R., Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. Journal of Neuroscience 2009, 29:6964-6972.
371. Zeng L.H., Xu L., Gutmann D.H., Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Annals of Neurology 2008, 63:444-453.
372. Zengi A., Ercan G., Caglayan O., Tamsel S., Karadeniz M., Simsir I., Harman E., Kahraman C., Orman M., Cetinkalp S., Ozgen G. Increased oxidative DNA damage in lean normoglycemic offspring of type 2 diabetic patients. Experimental and Clinical Endocrinology & Diabetes 2011, 119:467-471.
373. Zhang D., Contu R., Latronico M.V., Zhang J., Rizzi R., Catalucci D., Miyamoto S., Huang K., Ceci M., Gu Y., Dalton N.D., Peterson K.L., Guan K.L., Brown J.H., Chen J., Sonenberg N., Condorelli G. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. Journal of Clinical Investigation 2010, 120:2805-2816.
374. Zhang F., Ding T., Yu L., Zhong Y., Dai H., Yan M. Dexmedetomidine protects against oxygen-glucose deprivation-induced injury through the I2 imidazoline receptor-PI3K/AKT pathway in rat C6 glioma cells. Journal of Pharmacy and Pharmacology 2012, 64:120-127.
375. Zhang G., Zhao Z., Gao L., Deng J., Wang B., Xu D., Liu B., Qu Y., Yu J., Li J., Gao G. Gypenoside attenuates white matter lesions induced by chronic cerebral hypoperfusion in rats. Pharmacology Biochemistry & Behavior 2011, 99:42-51.
376. Zhao Y., Xiong X., Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Molecular Cell 2011, 44:304-316.
377. Zhou J., Su P., Wang L., Chen J., Zimmermann M., Genbacev O., Afonja O., Horne M.C., Tanaka T., Duan E., Fisher S.J., Liao J., Chen J., Wang F. mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proceedings of the National Academy of Sciences United States of America 2009, 106:7840-7845.
378. Zhou X., Wang L., Wang M., Xu L., Yu L., Fang T., Wu M. Emodin-induced microglial apoptosis is associated with TRB3 induction. Immunopharmacology and Immunotoxicology 2011, 33:594-602.
379. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Reviews Molecular and Cellular Biology 2011, 12:21-35.
380. Zou Z.Q., Zhang L.N., Wang F., Bellenger J., Shen Y.Z., Zhang X.H. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Molecular Medicine Reports 2012, 5:503-508.
381. Zwaal R.F., Comfurius P., Bevers E.M. Surface exposure of phosphatidylserine in pathological cells. Cellular and Molecular Life Sciences 2005, 62:971-988.